Amplifon expects to complete the acquisition of GN Hearing by the end of 2026. Images: Timon/stock.adobe.com and GN. The European Commission has approved Amplifon’s acquisition of GN’s hearing aid business, marking the final regulatory clearance required to complete the transaction. The Italian hearing aid retail network and the Danish company both released media releases on 6 November 2026 announcing the news....
Continue reading at Hearing Practitioner Australia
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a regulatory approval of a corporate acquisition with no immediate impact on clinical practice.
This merger concentrates significant retail and manufacturing power within a single hearing healthcare company, potentially reshaping supplier relationships, product availability, and competitive dynamics for independent clinics and dispensers across Europe and beyond.
- 01The European Commission has granted final regulatory approval for Amplifon's acquisition of GN's hearing aid business.
- 02The deal is expected to close by the end of 2026.
- 03Amplifon is already one of the world's largest hearing care retail chains; GN is a major hearing aid manufacturer.
- 04The merger increases vertical integration, combining a major retailer with a device manufacturer.
- 05Independent clinics and competing manufacturers may face shifts in market competition and product supply.
The European Commission has granted final regulatory approval for Amplifon's acquisition of GN's hearing aid business.
press releasesupportedThe deal is expected to close by the end of 2026.
press releasesupported
